Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of ALX-001 (BMS-984923) in Healthy Older Adults
NCT05817643Phase 1Active, not recruiting
- Sponsor
- Allyx Therapeutics
- Start
- Jan 2023
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BMS-9894923 in Alzheimer's disease (AD) (2 arms), sponsored by Allyx Therapeutics. Primary endpoints: Maximum Plasma Concentration up to 10 days, Time of Cmax up to 10 days and 1 more. Started Jan 2023; status: active, not recruiting.
02
Drugs
BMS-9894923
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05817643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05817643.